GENENTECH INC.;BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
发明人:
申请号:
IL25874118
公开号:
IL258741D0
申请日:
2018.04.16
申请国别(地区):
IL
年份:
2018
代理人:
摘要:
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.